Effective Treatment of Metastatic Melanoma by Combining MAPK and PI3K Signaling Pathway Inhibitors

被引:29
|
作者
Aasen, Synnove Nymark [1 ,2 ]
Parajuli, Himalaya [1 ]
Tuyen Hoang [1 ]
Feng, Zichao [1 ,3 ]
Stokke, Krister [1 ]
Wang, Jiwei [1 ,3 ]
Roy, Kislay [1 ]
Bjerkvig, Rolf [1 ,4 ]
Knappskog, Stian [2 ,5 ]
Thorsen, Frits [1 ,4 ,6 ]
机构
[1] Univ Bergen, Kristian Gerhard Jebsen Brain Tumour Res Ctr, Dept Biomed, Jonas Lies Vei 91, N-5009 Bergen, Norway
[2] Haukeland Hosp, Dept Oncol & Med Phys, Jonas Lies Vei 65, N-5021 Bergen, Norway
[3] Shandong Univ, Brain Sci Res Inst, 44 Wenhuaxi Rd, Jinan 250100, Shandong, Peoples R China
[4] Luxembourg Inst Hlth, Dept Oncol, NorLux Neurooncol Lab, 84 Val Fleuri, L-1526 Luxembourg, Luxembourg
[5] Univ Bergen, Sect Oncol, Dept Clin Sci, N-5020 Bergen, Norway
[6] Univ Bergen, Dept Biomed, Mol Imaging Ctr, Jonas Lies Vei 91, N-5009 Bergen, Norway
关键词
melanoma; brain metastasis; BRAF; MAPK; PI3K; combined treatment; apoptosis; CANCER CELLS; ACQUIRED-RESISTANCE; BUPARLISIB BKM120; BRAIN METASTASIS; DOSE-ESCALATION; IN-VITRO; MEK; APOPTOSIS; EXPRESSION; SURVIVIN;
D O I
10.3390/ijms20174235
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Malignant melanoma is the most aggressive type of skin cancer and is closely associated with the development of brain metastases. Despite aggressive treatment, the prognosis has traditionally been poor, necessitating improved therapies. In melanoma, the mitogen activated protein kinase and the phosphoinositide 3-kinase signaling pathways are commonly altered, and therapeutically inhibiting one of the pathways often upregulates the other, leading to resistance. Thus, combined treatment targeting both pathways is a promising strategy to overcome this. Here, we studied the in vitro and in vivo effects of the PI3K inhibitor buparlisib and the MEK1/2 inhibitor trametinib, used either as targeted monotherapies or in combination, on patient-derived melanoma brain metastasis cell lines. Scratch wound and trans-well assays were carried out to assess the migratory capacity of the cells upon drug treatment, whereas flow cytometry, apoptosis array and Western blots were used to study apoptosis. Finally, an in vivo treatment experiment was carried out on NOD/SCID mice. We show that combined therapy was more effective than monotherapy. Combined treatment also more effectively increased apoptosis, and inhibited tumor growth in vivo. This suggests a clinical potential of combined treatment to overcome ceased treatment activity which is often seen after monotherapies, and strongly encourages the evaluation of the treatment strategy on melanoma patients with brain metastases.
引用
收藏
页数:19
相关论文
共 50 条
  • [41] Treatment of keloids through Runx2 siRNA-induced inhibition of the PI3K/AKT signaling pathway
    Lv, Wenchang
    Wu, Min
    Ren, Yuping
    Luo, Xiao
    Hu, Weijie
    Zhang, Qi
    Wu, Yiping
    MOLECULAR MEDICINE REPORTS, 2021, 23 (01) : 1 - 13
  • [42] CoA Synthase is in complex with p85αPI3K and affects PI3K signaling pathway
    Breus, Oksana
    Panasyuk, Ganna
    Gout, Ivan T.
    Filonenko, Valeriy
    Nemazanyy, Ivan
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2009, 385 (04) : 581 - 585
  • [43] The PI3K/Akt/mTOR pathway as a preventive target in melanoma brain metastasis
    Tehranian, Cedric
    Fankhauser, Laura
    Harter, Patrick N.
    Ratcliffe, Colin D. H.
    Zeiner, Pia S.
    Messmer, Julia M.
    Hoffmann, Dirk C.
    Frey, Katharina
    Westphal, Dana
    Ronellenfitsch, Michael W.
    Sahai, Erik
    Wick, Wolfgang
    Karreman, Matthia A.
    Winkler, Frank
    NEURO-ONCOLOGY, 2022, 24 (02) : 213 - 225
  • [44] Diosgenin inhibits melanogenesis through the activation of phosphatidylinositol-3-kinase pathway (PI3K) signaling
    Lee, Jongsung
    Jung, Kwangseon
    Kim, Yeong Shik
    Park, Deokhoon
    LIFE SCIENCES, 2007, 81 (03) : 249 - 254
  • [45] Gambogic acid exhibits anti-metastatic activity on malignant melanoma mainly through inhibition of PI3K/Akt and ERK signaling pathways
    Li, Chun-yu
    Wang, Qi
    Wang, Xiao-min
    Li, Guo-xia
    Shen, Shen
    Wei, Xiao-lu
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2019, 864
  • [46] Inhibition of glycolytic metabolism in glioblastoma cells by Pt3glc combinated with PI3K inhibitor via SIRT3-mediated mitochondrial and PI3K/Akt-MAPK pathway
    Wang, Gang
    Fu, Xing-Li
    Wang, Jun-Jie
    Guan, Rui
    Sun, Yan
    To, Shing-shun Tony
    JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (05) : 5888 - 5903
  • [47] Inhibition of the PI3K/AKT signaling pathway sensitizes diffuse large B-cell lymphoma cells to treatment with proteasome inhibitors via suppression of BAG3
    Yuan, Ting
    Zhang, Feng
    Zhou, Xiangxiang
    Li, Ying
    Zhang, Ya
    Xu, Yangyang
    Wang, Xin
    ONCOLOGY LETTERS, 2019, 17 (04) : 3719 - 3726
  • [48] Sulforaphane Attenuates Endometriosis in Rat Models Through Inhibiting PI3K/Akt Signaling Pathway
    Zhou, Aixiu
    Hong, Yiting
    Lv, Yuchun
    DOSE-RESPONSE, 2019, 17 (02):
  • [49] Targeted disruption of PI3K/Akt/mTOR signaling pathway, via PI3K inhibitors, promotes growth inhibitory effects in oral cancer cells
    Sadhna Aggarwal
    Sarah John
    Leena Sapra
    Suresh C. Sharma
    Satya N. Das
    Cancer Chemotherapy and Pharmacology, 2019, 83 : 451 - 461
  • [50] RMEL3, a novel BRAFV600E-associated long noncoding RNA, is required for MAPK and PI3K signaling in melanoma
    Goedert, Lucas
    Pereira, Cristiano G.
    Roszik, Jason
    Placa, Jessica R.
    Cardoso, Cibele
    Chen, Guo
    Deng, Wanleng
    Yennu-Nanda, Vashisht Gopal
    Silva, Wilson A., Jr.
    Davies, Michael A.
    Espreafico, Enilza M.
    ONCOTARGET, 2016, 7 (24) : 36711 - 36718